Clinical Trials

Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma


Link : https://www.clinicaltrials.gov/ct2/show/NCT05218499
Status : CLOSED
Population : Dedifferentiated liposarcoma
Description : I 907828 vs doxorubicin as first line therapy in DDLPS
PI : A. Razak, J. Noujaim, A. Smrke
Centers Opened : Princess Margaret Cancer Centre, Hôpital Maisonneuve-Rosemont, BC Cancer
Phase : II/III
IIST/Pharma : Pharma